Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

COPENHAGEN (Reuters) - Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed.